Baylor College of Medicine, Houston, Texas, USA.
Therap Adv Gastroenterol. 2011 May;4(3):177-84. doi: 10.1177/1756283X11398736.
Iron deficiency is the single most prevalent nutritional deficiency worldwide. It accounts for anemia in 5% of American women and 2% of American men. The goal of this review article is to assist practitioners in understanding the physiology of iron metabolism and to aid in accurately diagnosing iron deficiency anemia. The current first line of therapy for patients with iron deficiency anemia is oral iron supplementation. Oral supplementation is cheap, safe, and effective at correcting iron deficiency anemia; however, it is not tolerated by some patients and in a subset of patients it is insufficient. Patients in whom the gastrointestinal blood loss exceeds the intestinal ability to absorb iron (e.g. intestinal angiodysplasia) may develop iron deficiency anemia refractory to oral iron supplementation. This population of patients proves to be the most challenging to manage. Historically, these patients have required numerous and frequent blood transfusions and suffer end-organ damage resultant from their refractory anemia. Intravenous iron supplementation fell out of favor secondary to the presence of infrequent but serious side effects. Newer and safer intravenous iron preparations are now available and are likely currently underutilized. This article discusses the possible use of intravenous iron supplementation in the management of patients with severe iron deficiency anemia and those who have failed oral iron supplementation.
缺铁是全球最普遍的营养缺乏症。它导致 5%的美国女性和 2%的美国男性贫血。本文的目的是帮助医生了解铁代谢的生理学,并帮助准确诊断缺铁性贫血。目前缺铁性贫血患者的一线治疗方法是口服铁补充剂。口服补充剂便宜、安全且有效,能纠正缺铁性贫血;然而,有些患者无法耐受,在一部分患者中效果不足。胃肠道失血超过肠道吸收铁能力的患者(例如,肠血管瘤)可能会发展为对口服铁补充剂难治的缺铁性贫血。这类患者最难处理。从历史上看,这些患者需要多次频繁输血,并因难治性贫血而导致终末器官受损。由于存在罕见但严重的副作用,静脉铁补充剂的应用已经减少。现在有更新、更安全的静脉铁制剂,而且可能尚未得到充分利用。本文讨论了静脉铁补充剂在严重缺铁性贫血患者和口服铁补充剂治疗失败患者中的可能应用。